US Executive Compensation Proxy SEC Filings — July 14, 2026
The three proxy filings reveal a stark contrast in corporate governance and shareholder risk. GRAHAM CORP and Powerlaw Corp. present routine, low-materiality annual meetings with standard director elections and neutral sentiment, indicating stable, predictable governance. In sharp contrast, Creative Medical Technology Holdings (CELZ) presents a high-stakes special meeting with two proposals that would massively dilute existing shareholders—authorized shares increasing 4x and full exercise of deeply discounted warrants. The period-over-period data shows CELZ has only 4.7M shares outstanding but 10.6M shares already committed via warrants/options, creating an overhang of 224% of current float. The insider activity data reveals no insider buying to offset the dilution risk, while the forward-looking data indicates the company seeks flexibility for capital raising with no specific commitments, suggesting potential cash burn concerns. The portfolio-level pattern is a governance divergence: established industrial/tech firms maintain status quo, while a micro-cap biotech pursues aggressive capital structure changes that could destroy shareholder value.